108 results
Page of 9
  • A011104

    Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer.

    For inquiries, call (732) 557-8294
    • Community Medical Center
  • A011202

    A Randomized Phase III Trial Comparing Axillary Dissection To Axillary Radiation In Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

    For inquiries, call (973) 926-7230
    • Newark Beth Israel Medical Center
  • A011202

    A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy

    For inquiries, call (908) 685-2481
    • RWJ University Hospital Somerset
  • A011401

    Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

    The Breast cancer Weight Loss (BWEL) Study

    For inquiries at Newark Beth Israel Medical Center, call (973) 926-7230

    For inquiries at Monmouth Medical Center, call (732) 923-6564

    • Monmouth Medical Center
    • Newark Beth Israel Medical Center
  • A011401 / BWel Trial

    Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer

    For inquiries, call (908) 685-2481
    • RWJ University Hospital Somerset
  • A011502 / ABC Trial

    A Randomized Phase III Double-Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

    For inquiries at Newark Beth Israel Medical Center, call (973) 926-7230

    For inquiries at Monmouth Medical Center, call (732) 923-6564

    For inquiries at RWJ Somerset Medical Center, call (908) 685-2481

    For inquiries at Community Medical Center, call (732) 557-8294

    • Monmouth Medical Center
    • Community Medical Center
    • Newark Beth Israel Medical Center
    • RWJ University Hospital Somerset
  • A021703 SOLARIS

    Randomized double-blind phase III trial of vitamin D3 supplementation in patients with previously untreated metastatic colorectal cancer (SOLARIS)

    For inquiries, call (732) 557-8294
    • Community Medical Center
  • A041702

    A041702 A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib plus Venetoclax and Obinutuzumab in Untreated Older Patients (≥ 70 Years of Age) with Chronic Lymphocytic Leukemia (CLL)” (NCT # NCT03737981)

    For inquiries, call (732) 923-6564
    • Monmouth Medical Center
  • A051701

    Randomized Phase II/III Study of Venetoclax (ABT 199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double-Expressing Lymphomas.

    Inclusion Criteria

    •  Pathologic diagnosis of Diffuse Large B-cell lymphoma (DLBCL) or High grade B-cell lymphoma (HGBCL)
    •  Double Hit Lymphoma (DHL) or Double Expressing Lymphoma (DEL)
      •  DHL is defined as high grade B-cell lymphoma with one of the below:
    •  Translocations of MYC and BCL2
    •  Translocations of MYC and BCL2 and BCL6 (triple hit lymphoma)
    •  Translocations of MYC and BCL6 without BCL2 translocation BUT with IHC expression of BCL2 (≥50%)


    Exclusion Criteria

    •  No prior treatment for DLBCL/HGBCL is allowed with the exception of corticosteroids administered for palliation, or a single cycle of either R-CHOP or DA-EPOCH-R administered prior to enrollment.

    For inquiries, call (973) 322-2470
  • A081105

    Randomized Study of Erlotinib Vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

    For inquiries, call (908) 685-2481
    • RWJ University Hospital Somerset
  • A081105

    A Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC).

    For inquiries, call (732) 557-8294
    • Community Medical Center
  • A151216

    Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

    For inquiries, call (732) 557-8294
    • Community Medical Center
Page of 9